Dupilumab + Placebo + Fexofenadine (loratadine if not available)
Phase 3Recruiting 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Pruritus
Conditions
Pruritus
Trial Timeline
Feb 15, 2022 โ Aug 25, 2027
NCT ID
NCT05263206About Dupilumab + Placebo + Fexofenadine (loratadine if not available)
Dupilumab + Placebo + Fexofenadine (loratadine if not available) is a phase 3 stage product being developed by Sanofi for Pruritus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05263206. Target conditions include Pruritus.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05263206 | Phase 3 | Recruiting |
Competing Products
20 competing products in Pruritus